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SObjective: Local recurrence limits long-term survival in patients with malignant pleural mesothelioma. We
investigated whether hyperthermic intraoperative cisplatin chemotherapy lavage affects the interval to recur-
rence and overall survival among patients with favorable prognostic factors.
Methods: Using a preoperative risk assessment algorithm we had previously developed and validated, we ret-
rospectively identified a cohort of patients treated with cytoreductive surgery from 2001 to 2009. The patients
had epithelial histologic findings on biopsy and were characterized as having a low risk of early recurrence and
death (ie, tumor volume 500 cm3 and were either men with a hemoglobin level of 13 g/dL or were women).
Those patients who had received hyperthermic intraoperative cisplatin chemotherapy were compared with
a comparison group of those who had not. Fisher’s exact test was used to determine the balance of prognostic
factors. The Kaplan-Meier method and log-rank tests were used to estimate and compare the interval to recur-
rence and overall survival. Cox proportional hazards regression was used for multivariate analysis.
Results: The cohort criteria identified 103 patients: 72 who received hyperthermic intraoperative cisplatin che-
motherapy and 31 who did not. The groups were balanced for prognostic factors, except for the use of neoadju-
vant chemotherapy (more common in the comparison group). The hyperthermic intraoperative cisplatin
chemotherapy group exhibited a significantly longer interval to recurrence (27.1 vs 12.8 months) and overall
survival (35.3 vs 22.8 months) than the comparison group. The improved interval to recurrence and overall
survival for the hyperthermic intraoperative cisplatin chemotherapy group were particularly evident among
the subgroups of patients who had not received hemithoracic radiotherapy and who had pathologic stage N1
or N2 lymph node metastases.
Conclusions: A favorable outcome and minimal incremental morbidity support the incorporation of hyperther-
mic intraoperative cisplatin chemotherapy into multimodality treatment strategies for patients with low-risk
epithelial malignant pleural mesothelioma. (J Thorac Cardiovasc Surg 2013;145:955-63)Malignant pleural mesothelioma (MPM) is a rare, locally
aggressive, and rapidly fatal tumor of the thoracic pleural
mesothelium commonly associated with inhalational expo-
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The Journal of Thoracic and Casurgical macroscopic complete resection1 using either ex-
trapleural pneumonectomy combined with chemotherapy
and radiotherapy or pleurectomy/decortication combined
with chemotherapy have been associated with long-
duration disease remission and overall survival for selected
patients.2 The tendency for eventual relapse to occur locally
in most cases3 has prompted us and others to investigate the
use of additional modalities to improve local control. Dur-
ing the past decade, we have completed a series of phase I
and II trials of hyperthermic intraoperative chemotherapy
(HIOC) lavage, initially using cisplatin as a single agent.4-6
In the present retrospective study, we sought to determine
whether this intervention had a measurable effect on
patient outcomes.
The outcomes for patients withMPMwho undergo surgi-
cal resection have varied, reflecting the heterogeneity of this
tumor with regard to the prognostic factors, including gen-
der,7,8 histologic features,9 tumor burden, anemia, and therdiovascular Surgery c Volume 145, Number 4 955
Abbreviations and Acronyms
CT ¼ computed tomography
HIOC ¼ hyperthermic intraoperative cisplatin
chemotherapy
MPM ¼ malignant pleural mesothelioma
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Sdelivery of adjunctive treatments.10 Tominimize competing
sources of variance and thereby improve the likelihood of
detecting an effect of a single dose of intraoperative cisplatin
monotherapy, we identified a cohort of patients at low risk of
early recurrence and death after macroscopic complete
resection and multimodality therapy. Previously, we devel-
oped and validated a preoperative risk assessment algorithm
that includes the computed tomography (CT)-derived tumor
volume, hemoglobin level, and gender for patients with ep-
ithelial MPM diagnosed using pleural biopsy.11 This algo-
rithm was applied retrospectively to identify, for the
present analysis, a cohort of patients with a low preoperative
risk of early recurrence and death.Within this cohort, we in-
vestigated whether patients who had receivedHIOC demon-
strated a longer interval to recurrence and/or overall survival
compared with patients who had not.METHODS
With institutional review board approval (protocol no. 2005-p-001520),
a study cohort was selected to include all patients within the Brigham and
Women’s Hospital International Mesothelioma Program Patient Data Reg-
istry who (1) had epithelial MPM as determined by biopsy; (2) had under-
gone intended multimodality therapy from 2001 to 2009, involving
macroscopic complete resection with neoadjuvant or adjuvant intravenous
chemotherapy and/or radiotherapy; (3) had complete data available for risk
assessment (preoperative tissue biopsy findings, preoperative CT scan
available electronically for tumor volume calculation, preoperative labora-
tory findings, gender) and outcomes analysis (MPM recurrence and vital
status follow-up); and (4) were categorized as preoperative low risk
(defined as epithelial histologic features by biopsy, computed tumor vol-
ume 500 cm3, and either male gender with a hemoglobin level of
13 g/dL or female gender).11 The cohort was divided into 2 groups
according to whether HIOC had been administered during the operative
procedure after tumor removal. The patients who received HIOC were
treated using 1 of 4 treatment protocols active during the portions of the
study period (protocol 99-1244 [1 patient], protocol 01-1165 [5 patients],
protocol 03-3026 [24 patients], and protocol 04-063 [2 patients]) or off pro-
tocol using protocol-established safe and effective dose and administration
parameters. These parameters included macroscopic complete resection
followed by cisplatin 175 to 225 mg/m2 for a 1-hour lavage at 42C with
sodium thiosulfate rescue and/or amifostine protection.4,6 The control
patients had undergone macroscopic complete resection and intended
adjuvant and/or neoadjuvant therapy but had not received cisplatin HIOC.
Preoperatively, all patients underwent pleural biopsy and CT imaging.
Most also underwent cervical mediastinoscopy. Some patients with posi-
tive mediastinal nodal disease on preoperative mediastinoscopy were
referred for induction chemotherapy. Other patients had received chemo-
therapy before referral. The choice of operative procedure was determined
for each patient from the preoperative assessment findings. Pleurectomy/
decortication was recommended for patients in whom that procedure was
judged likely to obtain macroscopic complete resection—generally956 The Journal of Thoracic and Cardiovascular Surgpatients with low-volume tumor not apparently involving the lung paren-
chyma and/or fissures—and those patients with contraindications to pneu-
monectomy. The follow-up schedule for all patients consisted of several
visits in the early postoperative period, once every 4 months with CT for
3 years, and every 6 months with CT thereafter. The patients who devel-
oped symptoms between the surveillance visits were evaluated with addi-
tional imaging, as appropriate.
Categorical or dichotomized continuous variables representing demo-
graphic, clinical, and pathologic covariates were assessed for the propor-
tionality of the distribution between the HIOC and comparison groups
using Fisher’s exact test. In addition to the variables defining low risk
(histologic subtype by biopsy, CT-derived tumor volume, gender, and he-
moglobin level), the histologic subtype found on the final pathologic exam-
ination, pathologic lymph node status, stage, age, length of hospital stay,
administration of adjuvant and/or neoadjuvant therapy, surgical procedure,
and perioperative mortality were also assessed.
A central review of all preoperative radiographic studies and available
studies for evaluation of recurrence status (82 patients [80%]) was per-
formed by a thoracic radiologist (R.G.). The recurrence-free interval was
calculated as the interval from surgery to the first radiographic recurrence
or biopsy determination of recurrence, with censoring on the date of the
most recent study if recurrence was not demonstrated, the patient was sub-
sequently lost to follow-up, or the date of death if other-cause death was
documented (eg, no recurrent mesothelioma at autopsy). Overall survival
was calculated as the interval from surgery to death from any cause, with
censoring for living patients at the most recent contact date. Kaplan-
Meier survival function estimates were calculated and compared using
the log-rank statistic. Multivariate analysis was performed using Cox pro-
portional hazards regression.RESULTS
From 2001 through 2009, 616 patients underwent macro-
scopic complete resection by either extrapleural pneumonec-
tomy or pleurectomy/decortication. Of these, 303 patients
(207 of whom received cisplatin HIOC) had the preoperative
hemoglobin level andCTdata available for tumorvolumecal-
culation and could thus be evaluated retrospectively for pre-
operative risk. The demographic, clinical, treatment, and
pathologic characteristics of the 103 patients who had epithe-
lial MPM diagnosed by the biopsy findings and were charac-
terized as low risk, thereby fitting the criteria for inclusion in
the study cohort, are listed in Table 1. The low-risk patients
who underwent extrapleural pneumonectomy and could be
pathologically staged using the International Mesothelioma
Interest Group TNM criteria12 included 1 patient with stage
I (1%), 13 with stage II (18%), 39 with stage III (53%),
and 21 with stage IV (28%). The median interval to recur-
rence for the low-risk cohort was 23.6 months after surgery,
and the median overall survival was 33.1 months.
Among the 103 low-risk patients, 72 received cisplatin
HIOC and constituted the treatment group, and 31 under-
went macroscopic complete resection without HIOC and
constituted the comparison group. The decision to treat
with HIOC was determined on an individual basis. The
most common reason that comparison patients did not re-
ceive HIOC was previous administration of neoadjuvant
platinum-containing chemotherapy (13 patients). The
groups were not balanced in this respect—42% of theery c April 2013
TABLE 1. Demographic, clinical, treatment, and pathologic characteristics
Characteristic Cohort HIOC group Comparison group P value
Patients (n) 103 72 31
Age (y)
Median 62 61 66
Range 27-84 27-79 45-84
Age 62 y — 33 (46%) 20 (65%) .09
Male gender (n) 68 (66%) 48 (67%) 20 (65%) .82
Surgical procedure (n) .63
EPP 74 (72%) 53 (74%) 21 (68%)
P/D 29 (28%) 19 (26%) 10 (32%)
Right side (n) 47 (46%) 30 (42%) 17 (55%) .28
Pathologic subtype (n) .24
Epithelial 87 (84%) 63 (88%) 24 (77%)
Biphasic 16 (16%) 9 (13%) 7 (23%)
Pathologic lymph node status (n) >.99
Nx 23 (22%) 15 (21%) 8 (26%)
N0 37 (36%) 26 (36%) 11 (35%)
N1 19 (18%) 15 (21%) 4 (13%)
N2 23 (22%) 15 (21%) 8 (26%)
Nþ (station unspecified) 1 (1%) 1 (1%) 0
Node positive (N1, N2, Nþ vs N0) — 31 (55%) 12 (52%)
Pathologic TNM stage (EPP only) (n) .52
I 1 (1%) 1 (1%) 0
II 13 (18%) 8 (15%) 5 (24%)
III 39 (53%) 29 (55%) 10 (48%)
IV 21 (28%) 15 (28%) 6 (29%)
Stage III-IV (vs I-II) — 44 (83%) 16 (76%)
Length of hospital stay (d)
Median 12 11 12
Range 6-84 6-84 6-62
Length of stay 12 d 34 (47%) 18 (58%) .39
Neoadjuvant chemotherapy (n) 23 (22%) 10 (14%) 13 (42%) .0037
Adjuvant chemotherapy (n) .13
Unknown (lost to follow-up) 1 (1%) 0 1 (3%)
No adjuvant chemotherapy 49 (48%) 31 (43%) 18 (58%)
Adjuvant chemotherapy 53 (51%) 41 (57%) 12 (39%)
Adjuvant radiotherapy (n) .28
Unknown (lost to follow-up) 1 (1%) 0 1 (3%)
No adjuvant radiotherapy 48 (47%) 31 (43%) 17 (52%)
Adjuvant radiotherapy 54 (52%) 41 (57%) 13 (45%)
Perioperative (30-d or in-hospital) mortality (n) 3 (3%) 3 (4%) 0 .55
Preoperative hemoglobin level (g/dL)
Median 13.8 13.9 13.6
Range 8.7-16.6 8.7-16.6 10.0-16.1
Preoperative hemoglobin level 13.8 g/dL 36 (50%) 19 (61%) .39
Preoperative tumor volume (cm3)
Median 112 107 146
Range 1-478 1-478 4-470
Preoperative tumor volume 112 cm3 34 (47%) 17 (55%) .67
Two-sided P values given for between-subgroup comparisons for categorical and dichotomized continuous variables (Fisher’s exact test). HIOC, Hyperthermic intraoperative
cisplatin chemotherapy; EPP, extrapleural pneumonectomy; P/D, pleurectomy/decortication; TNM, tumor-node-metastasis.
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platinum-based chemotherapy compared with 14% of pa-
tients in the HIOC group (P¼ .0037).Most commonly, neo-
adjuvant chemotherapy consisted of pemetrexed plusThe Journal of Thoracic and Cacisplatin (18 patients) for a median of 4 cycles (range,
1-8), and 2 of these patients also received other chemother-
apy regimens before surgery. Four patients received peme-
trexed plus carboplatin for a median of 6 cycles (range, 4-6);rdiovascular Surgery c Volume 145, Number 4 957
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unknown. Other reasons for not receiving HIOC included
borderline renal function and patient choice.
All other demographic, clinical, and pathologic variables
with established or potential influence on recurrence and/or
survival endpoints were distributed proportionally between
the 2 groups (Table 1). These included gender,8 age,7 surgi-
cal procedure, administration of adjuvant chemotherapy
and/or radiotherapy (Table 2),10 pathologic World Health
Organization subtype,13 lymph node status,14 and Interna-
tional Mesothelioma Interest Group/American Joint
Committee on Cancer/International Union Against Cancer
TNM stage.12
The groups also did not differ significantly in terms of the
hospital length of stay (as a surrogate measure of postoper-
ative morbidity) or perioperative mortality. Although not
statistically significant, the only 3 postoperative deaths oc-
curred in the HIOC cohort. None of thesewere thought to be
related to the HIOC. Specifically, 1 patient had constrictive
pericarditis, 1 died of bronchopleural fistula/empyema, and
1 died of an intracranial hemorrhage after a prolonged
intensive care unit stay with multiorgan dysfunction after
intraoperative right ventricular failure.
At the analysis, 45 of 72 (63%) patients who had re-
ceived HIOC had experienced MPM recurrence. Of the
72 patients in the HIOC group, 27 (38%) were censored
for recurrence. Of these 27 patients, 13 (18%) had died
of other causes, including 3 perioperative deaths (4.2%),
3 (4.2%) were lost to follow-up and died with an unknown
recurrence status, and 11 (15%) remained alive in active
follow-up without evidence of recurrence at a median
postoperative interval of 54 months (range, 26-94 months).
Of the 31 comparison patients, 23 (74%) developed recur-
rence, and 8 (26%) were censored: 4 (13%) were lost to
follow-up, and 4 (13%) died of other causes. Three com-
parison group patients (10%) were alive (with recurrence)
at a median postoperative interval of 39 months (range,
38-75 months).TABLE 2. Details of adjuvant chemotherapy and radiotherapy
administered to cohort patients
Variable Patients (n) Median (range)
Adjuvant chemotherapy Cycles (n)
Cisplatin (concurrent with RT) 3 4 (3-4)
Cisplatin þ gemcitabine 2 1.5 (1-2)
Cisplatin þ pemetrexed 39 4 (1-6)
Carboplatin þ pemetrexed 6 4 (3-9)
Unspecified 3 —
Adjuvant radiotherapy Total dose (cGy)
AP/PA 1 5400
MSKCC 18 5400 (3420-5400)
IMRT 9 4860 (4500-5400)
Unspecified 26 —
RT, Radiotherapy; AP/PA, anteroposterior/posteroanterior (fields); MSKCC, Memo-
rial Sloan-Kettering Cancer Center; IMRT, intensity-modulated RT.
958 The Journal of Thoracic and Cardiovascular SurgA significantly longer interval to recurrence was ob-
served for the HIOC group (median, 27.1 months) relative
to the comparison group (median, 12.8 months;
P ¼ .0084; Figure 1, A). Among the subgroup of patients
who received induction or adjuvant chemotherapy but no
radiotherapy, the HIOC group experienced a significantly
longer interval to recurrence than did the comparison group
(26.3 vs 10 months; P ¼ .013; Figure 1, B). However, no
significant differences were seen in the interval to recur-
rence between the HIOC and comparison groups for
patients who received radiotherapy in addition to chemo-
therapy (P¼ .14; Figure 1, C). Similarly, the HIOC patients
experienced a significantly longer time to recurrence than
did the comparison group among the subgroup of patients
with pathologic N1 or N2 disease (23.5 vs 11.1 months;
P ¼ .0012; Figure 1, D). The interval to recurrence for pa-
tients with pathologic N0 disease was similar for the HIOC
and comparison groups (P ¼ .27; Figure 1, E).
The patients in the HIOC group also had a longer overall
survival duration than the patients in the comparison group.
The median overall survival was 35.3 months for patients
who received HIOC versus 22.8 months for patients who
did not receive HIOC (P¼ .026; Figure 2, A). The subgroup
analysis of overall survival revealed a pattern of findings
similar to that observed with the interval to recurrence end-
point. A significantly longer survival duration was observed
for the HIOC group than for the comparison group among
the patients who had received chemotherapy but no radio-
therapy. The median overall survival was 51.1 months for
patients in the HIOC group and 20.6 months for those in
the comparison group in this subset (P ¼ .0042;
Figure 2, B). The overall survival for patients who had re-
ceived radiotherapy in addition to chemotherapy was not
significantly different between the HIOC and comparison
groups (36.4 vs 31.2 months; P ¼ .15; Figure 2, C). Longer
overall survival was observed for the HIOC group than for
the comparison group among the patients with pathologic
N1 or N2 disease, with a median overall survival of 33.1
versus 17.4 months, respectively (P ¼ .018; Figure 2, D).
Overall survival did not differ between the 2 groups for
those with pathologic N0 disease (36.4 vs 40.3 months;
P ¼ .71; Figure 2, E).
In the 2 groups, 9 HIOC patients (13%) and 7 compari-
son patients (23%) had biphasic histologic findings on the
final pathologic analysis (Fisher’s exact, P ¼ .24). Among
the patients with biphasic MPM, the median interval to re-
currence was 29.2 months for the HIOC group and 12.8
months for the comparison group (P ¼ .051; Figure 3, A).
The median overall survival for the biphasic subgroup
was 31.3 months for the HIOC patients and 18.9 months
for the comparison patients (P ¼ .086; Figure 3, B).
Based on the differential effects of HIOC observed
among patients treated with and without adjuvant therapy
in the subgroup analysis, Cox regression analysis was usedery c April 2013
FIGURE 1. Kaplan-Meier survival functions for hyperthermic intraoperative cisplatin chemotherapy (HIOC) and comparison groups depicting interval to
recurrence for (A) all patients, (B) patients who received adjuvant or neoadjuvant chemotherapy but no adjuvant radiotherapy, (C) patients who received
adjuvant or neoadjuvant chemotherapy and adjuvant radiotherapy, (D) patients with N1 or N2 lymph node metastasis demonstrated on final pathologic ex-
amination, and (E) patients with N0 status determined by final pathologic examination.
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ated with each of the possible combinations of HIOC
and adjuvant therapy, with the patients who did not receive
either therapy as the reference group. To control for the in-
dependent effects of previous therapy and established
prognostic factors, the regression model also included
neoadjuvant chemotherapy history, histologic findings,
and lymph node status. The multivariate analysis
(Table 3) revealed that a hazard ratio of 0.28 was associ-
ated with HIOC followed by adjuvant radiotherapy or che-
motherapy, suggesting that the risk of death is reduced by
more than 70% compared with macroscopic complete re-
section alone. Smaller survival benefits were observed forThe Journal of Thoracic and Capatients treated with either HIOC or adjuvant therapy but
not both; the corresponding hazard ratios of 0.64 and 0.48
suggested an approximately similar benefit for both thera-
peutic strategies.
DISCUSSION
With appropriate systemic protection, cisplatin HIOC
after surgical macroscopic complete resection is well-
tolerated by patients and does not increase the hospital
length of stay nor interfere with subsequent administration
of adjuvant chemotherapy and/or radiotherapy. In this co-
hort of patients with MPM and preoperative indicators of
low-risk disease (epithelial histologic findings on biopsy,rdiovascular Surgery c Volume 145, Number 4 959
FIGURE 2. Kaplan-Meier survival functions for hyperthermic intraoperative cisplatin chemotherapy (HIOC) and comparison groups depicting overall
survival for (A) all patients, (B) patients who received adjuvant or neoadjuvant chemotherapy but no adjuvant radiotherapy, (C) patients who received ad-
juvant or neoadjuvant chemotherapy and adjuvant radiotherapy, (D) patients with N1 or N2 lymph node metastasis demonstrated on final pathologic exam-
ination, and (E) patients with N0 status determined by final pathologic examination.
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gender with a hemoglobin level within normal limits), treat-
ment with HIOC was associated with an extended interval
to recurrence and overall survival.
It is well known that preoperative pleural biopsy has low
accuracy for detecting the histologic subtype of MPM.
Evenwhenmultiple biopsycores are taken to sampledifferent
anatomic areas, the presence of biphasic MPM will some-
times not be detected.15,16 Accordingly some patients in the
present study had biphasic histologic features demonstrated
on the final pathologic examination. Because of the known
influence of the histologic type on the outcome endpoints,
the potential contribution of the histologic type to the960 The Journal of Thoracic and Cardiovascular Surgobserved effects of HIOC was assessed in a subgroup
analysis. The interval to recurrence and overall survival in
this very small subgroup both displayed trends consistent
with the overall cohort results that approached statistical
significance, arguing that the histologic type did not
contribute to the observed effects of HIOC. Patients whose
tumor histologic type was inaccurately classified from the
pleural biopsy findings were likely to have had tumors with
a relatively minor sarcomatoid component, which can be as
low as 10% within the classification of biphasic MPM.9
Such patients appeared to have a prognosis approaching
that ofpatientswith tumors classified asepithelial (<10% sar-
comatoid component) in this low-risk cohort.ery c April 2013
FIGURE3. Kaplan-Meier survival functions for hyperthermic intraoperative cisplatin chemotherapy (HIOC) and comparison groups depicting (A) interval
to recurrence and (B) overall survival for patients found to have biphasic subtype tumors on final pathologic examination.
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tients who received neoadjuvant chemotherapy than did
the HIOC group. A number of the patients referred to our
program had already been treated with neoadjuvant
platinum-based chemotherapy, resulting, in some cases, in
deferral of additional intraoperative cisplatin. Because no
between-group differences were found in stage distribution
or lymph node status, the influence of this imbalance on the
outcomes, if any, would be expected to favor the compari-
son group. No influence of neoadjuvant chemotherapy on
overall survival was observed on multivariate analysis (haz-
ard ratio, 1.14).
Even among patients with early MPM who are the most
likely to have grossly negative margins at resection,17,18
macroscopic complete resection by either extrapleural
pneumonectomy or pleurectomy/decortication will, at best,
achieve R1 status. This is consistent with the fact that the
primary pattern of failure is local within the ipsilateral
hemithorax.3Consequently, aggressive systemicand local ad-
juvant treatment is often delivered to prevent or forestall
tumor recurrence. This adjuvant treatment is typically intra-
venous chemotherapy (after pleurectomy/decortication or
extrapleural pneumonectomy) and/or hemithoracic radiother-
apy (after extrapleural pneumonectomy only). HIOC repre-
sents a method of administering chemotherapy as an
additional ‘‘local’’ modality by applying a high concentration
of cytotoxic drug to potential microscopic disease at theTABLE 3. Multivariate analysis estimating effect on overall survival
associated with possible combinations of HIOC and adjuvant
therapy (patients not receiving either therapy as reference)
Covariate HR 95% CI
HIOC without adjuvant therapy 0.64 0.25-1.65
Adjuvant therapy without HIOC 0.48 0.20-1.13
HIOC with adjuvant therapy 0.28 0.12-0.65
Neoadjuvant chemotherapy 1.14 0.60-2.17
Lymph node involvement 1.69 1.02-2.82
Nonepithelial histologic features 1.56 0.84-2.92
HIOC, Hyperthermic intraoperative cisplatin chemotherapy; HR, hazard ratio; CI,
confidence interval.
The Journal of Thoracic and Casurface of the retained tissues, including the chest wall,
lung (pleurectomy/decortication), and lymph node metasta-
ses within the thoracic cavity, with a goal of effectively ex-
tending the achieved surgical resection margin by several
millimeters.
The beneficial effects of HIOC on the interval to recur-
rence and overall survival were particularly evident within
the subgroup of patients who had not received hemithoracic
radiotherapy. By contrast, the incremental benefit of cis-
platin HIOC was not significant among patients who under-
went extrapleural pneumonectomy with hemithoracic
radiotherapy and intravenous chemotherapy, in most cases
with a pemetrexed-platinum doublet. Adjuvant radiother-
apy might be expected to be more consistently efficacious
for local control than HIOC, because it is delivered to the
tissues at risk in multiple fractions for an extended period
up to a maximal tolerated cumulative dose, instead of a sin-
gle cisplatin exposure.
However, given the presence of many radiosensitive
structures in the hemithorax (ie, heart, esophagus, contralat-
eral lung, spinal cord, small bowel, and liver or stomach, de-
pending on laterality), it is technically very difficult to
deliver tumoricidal radiation doses to the entire target of
the hemithorax.19 Thus, depending on the radiation tech-
nique used, significant underdosing of certain areas can re-
sult, such as the mediastinum and inferior extent of the
costophrenic sulcus. The subgroup of patients with patho-
logic N1 or N2 lymph node metastases also demonstrated
a longer interval to recurrence and overall survival for the
HIOC group compared with the comparison group. The lat-
ter exhibited a survival duration similar to that previously
reported for node-positive patients with epithelial MPM
treated with trimodality therapy without HIOC.14 By con-
trast, among patients with lymph node-negative disease,
no statistically significant incremental effect of cisplatin
HIOCwas evident. One could posit that in patients with me-
diastinal and/or hilar lymph node involvement, radiother-
apy might be less effective owing to dose limitations
compared with those treated with HIOC, which directlyrdiovascular Surgery c Volume 145, Number 4 961
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Accordingly, treatment with HIOC would be associated
with incremental local control that will be most apparent
for patients with node-positive disease. In support of this
interpretation, the multivariate analysis demonstrated syn-
ergy between HIOC and adjuvant therapy in reducing the
hazard ratio for death.
Thus, the patients who might particularly benefit from
HIOC include those with pathologic N1-N2 disease and
those who do not receive postoperative radiotherapy. These
2 factors are often not known until after resection. The
lymph node status is determined by pathologic review.
The decision regarding the delivery of adjuvant radiother-
apy depends on many factors. Radiotherapy is often de-
ferred in certain scenarios, such as after pleurectomy, for
patients who have experienced postoperative complications
or adjuvant chemotherapy-related toxicity, and for those
who opt not to receive planned adjuvant radiotherapy. For
patients who undergo pleurectomy, full-dose hemithoracic
radiotherapy has not been demonstrated to be safe owing
to the sensitivity of the retained lung. Among patients
who underwent extrapleural pneumonectomy with adjuvant
radiotherapy, no significant survival benefit was found for
cisplatin HIOC, although the numbers of patients available
for subgroup analysis in the present study were too small to
draw definitive conclusions.
The decade-long early-phase experience with cisplatin
HIOC has enabled us to refine the perioperative manage-
ment of patients undergoing this treatment. Nephroprotec-
tion with fluid administration and the timing of amifostine
and sodium thiosulfate has enabled us to minimize the renal
toxicity of HIOC. Deep vein thrombosis surveillance has
also minimized thromboembolic complications. These ad-
aptations have enabled us to perform cytoreductive surgery
with HIOC with morbidity and mortality rates that do not
exceed those of cytoreductive surgery alone.4,6
The choice of cisplatin for the initial investigation of
HIOC was multifactorial. Cisplatin is the most active single
agent against mesothelioma,20 and it had been successfully
administered intrapleurally (although not intraoperatively)
by others in previous studies.21,22 When administered
intravenously, cisplatin has synergistic activity against
MPMwith doxorubicin,20 gemcitabine,23 and pemetrexed24
and might potentiate other modalities such as radiotherapy
and oncolytic viral therapy.25 The evidence for efficacy ob-
served in the present study with cisplatin alone encourages
additional investigation of this treatment paradigm using
combination strategies. Intraoperative lavage provides a ba-
sis for locally delivering high-dose combination regimens
that might incrementally enhance the efficacy, potentially
providing benefit to patients at greater risk and with nonepi-
thelial MPM. A phase I trial at our institution of cisplatin–
gemcitabine HIOC after macroscopic complete resection
has recently completed accrual, and assessments of other962 The Journal of Thoracic and Cardiovascular Surgcombination regimens, including cisplatin–pemetrexed,
are planned.
The present study was limited by its retrospective nature
and small sample size, particularly for the comparison
group. The low-risk cohort represented a highly selected
group of patients and inherent bias was present in using
the group of patients who did not receiveHIOC as a compar-
ison group. Moreover, the comparison group included sig-
nificantly more patients who had received neoadjuvant
chemotherapy, limiting the comparability of this cohort to
the patients who had received HIOC. The HIOC group in-
cluded patients treated on and off various protocols during
the study period. Patients were able to complete adjuvant
therapy with variable consistency, frequently at outside in-
stitutions. The inclusion of adjuvant therapy as a covariate
in the multivariate analysis was subject to guarantee time
bias,26 which might have resulted in an overestimation of
its relative influence on overall survival. These issues intro-
duced some variability and bias into the analysis that could
be overcome with a randomized prospective trial. However,
a prospective randomized trial is unlikely to be performed.
Overall, in evaluating our experience with cisplatin-only
HIOC, we have found that our data suggest (but do not
prove) that HIOC improves the outcomes of low-risk
patients with MPM.CONCLUSIONS
Among the low-risk patients, treatment with cisplatin
HIOC appears to be particularly beneficial for patients
with stage N1-N2 nodal involvement and for those who,
for whatever reason, do not undergo adjuvant therapy.
Both conditions are difficult to predict preoperatively be-
cause of the low sensitivity of the preoperative assessment,
imaging, and mediastinoscopy for detecting nodal disease
and the inherent difficulties associated with predicting post-
operative complications and intolerance to aggressive
multimodality therapy. Furthermore, cisplatin HIOC is
associated with a favorable toxicity profile. Thus, given
the favorable effects on outcomes reported and the minimal
incremental morbidity associated with cisplatin HIOC, we
recommend incorporation of HIOC into multimodality
treatment strategies for patients with low-risk epithelial
MPM and without specific contraindications.
The authors sincerely thank Ann S. Adams for expert editorial
assistance, and Drs Paul Sugarbaker, JohnMannick, Antoon Lerut,
Bryan Burt, Brian Goodman, and S. Osman Ali for their critical
comments on our report.References
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